

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Omega Fund V, L.P.</u> <hr/> (Last) (First) (Middle) 888 BOYLSTON ST. SUITE 1111 <hr/> (Street) BOSTON MA 02199 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/08/2020	3. Issuer Name and Ticker or Trading Symbol <u>Kronos Bio, Inc. [KRON]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	19,451	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series Seed Preferred Stock	(2)	(2)	Common Stock	1,606,220	(2)	D ⁽¹⁾	
Series A Preferred Stock	(2)	(2)	Common Stock	1,376,313	(2)	D ⁽¹⁾	
Convertible Promissory Note	(3)	02/20/2020	Common Stock	366,299	16.15	D ⁽¹⁾	

1. Name and Address of Reporting Person* <u>Omega Fund V, L.P.</u> <hr/> (Last) (First) (Middle) 888 BOYLSTON ST. SUITE 1111 <hr/> (Street) BOSTON MA 02199 <hr/> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>Omega Fund V GP, L.P.</u> <hr/> (Last) (First) (Middle) 888 BOYLSTON ST. SUITE 1111 <hr/> (Street) BOSTON MA 02199 <hr/> (City) (State) (Zip)		
--	--	--

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Omega Fund V GP Manager, Ltd.		
(Last)	(First)	(Middle)
888 BOYLSTON ST. SUITE 1111		
(Street)		
BOSTON	MA	02199
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Paster Anne-Mari		
(Last)	(First)	(Middle)
888 BOYLSTON ST. SUITE 1111		
(Street)		
BOSTON	MA	02199
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Nessi Claudio		
(Last)	(First)	(Middle)
888 BOYLSTON ST. SUITE 1111		
(Street)		
BOSTON	MA	02199
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Stampacchia Otello		
(Last)	(First)	(Middle)
888 BOYLSTON ST. SUITE 1111		
(Street)		
BOSTON	MA	02199
(City)	(State)	(Zip)

Explanation of Responses:

- Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega Fund V GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein.
- Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") is convertible into 1.055 shares of Common Stock. The Preferred Stock has no expiration date.
- The convertible promissory note will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's first firm commitment underwritten initial public offering.

Remarks:

[Omega Fund V, L.P.](#), by [10/08/2020](#)
[Omega Fund V GP, L.P.](#),
[its general partner](#), by
[Omega Fund V GP](#)
[Manager, Ltd.](#), its general

<u>partner, /s/ Anne-Mari Paster, Director</u>	
<u>Omega Fund V GP, L.P., by Omega Fund V GP Manager, Ltd., its general partner, /s/ Anne-Mari Paster, Director</u>	<u>10/08/2020</u>
<u>Omega Fund V GP Manager, Ltd., /s/ Anne-Mari Paster, Director</u>	<u>10/08/2020</u>
<u>/s/ Anne-Mari Paster</u>	<u>10/08/2020</u>
<u>/s/ Claudio Nessi</u>	<u>10/08/2020</u>
<u>/s/ Otello Stampacchia</u>	<u>10/08/2020</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.